Skip to content
PeptidesEncyclopedia
Informational, not medical advice

This is an approved / prescription medicine. Do not use without a prescription and medical supervision.

EMA-approvedaka TransCon PTH, Yorvipath

Palopegteriparatide — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Palopegteriparatide (also known as TransCon PTH) is a peptide catalogued under Hormones & Metabolic (Long-acting PTH prodrug). It is described as: PTH1R. Documented context: Hypoparathyroidism. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Palopegteriparatide?

Palopegteriparatide (also called TransCon PTH; brand name Yorvipath) is a long-acting prodrug that continuously releases PTH(1-34), the biologically active fragment of parathyroid hormone. It is approved for adults with chronic hypoparathyroidism, receiving EMA authorization in 2023 and FDA approval in 2024.

It is a prescription injectable, and its evidence base is human: the pivotal randomized phase 3 PaTHway trial with published 26-week, 52-week, and multi-year follow-up analyses.

How does Palopegteriparatide work?

Palopegteriparatide is an inert PTH(1-34) molecule transiently bound to a carrier that releases active hormone at a controlled rate, producing sustained, near-physiologic parathyroid hormone exposure over 24 hours.

This restores renal calcium reabsorption, phosphate excretion, and activation of vitamin D that are deficient in hypoparathyroidism.

What does the research say about Palopegteriparatide?

  • In the phase 3 PaTHway trial, palopegteriparatide normalized serum calcium while allowing most adults to stop conventional therapy (active vitamin D and therapeutic-dose calcium). [1]
  • Independence from active vitamin D and calcium supplementation with normal serum calcium was sustained through 52 weeks of treatment. [2]
  • Renal function (eGFR) improved over one year of treatment in adults with chronic hypoparathyroidism. [3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

  • [1] Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial — Khan AA et al., Journal of Bone and Mineral Research 2023. (Randomized controlled phase 3 trial)
  • [2] Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial — Clarke BL et al., Journal of Clinical Endocrinology and Metabolism 2025. (Randomized controlled phase 3 trial (52-week))
  • [3] Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial — Rejnmark L et al., Advances in Therapy 2024. (Phase 3 trial analysis (1-year))
  • [4] Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial — Rejnmark L et al., Journal of Bone and Mineral Research 2026. (Phase 3 trial analysis (2-year))
  • [5] Palopegteriparatide in Japanese adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway Japan trial — Ashida K et al., Endocrine Journal 2026. (Phase 3 multicenter trial)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In its approved use it is given as a once-daily subcutaneous injection that is individually titrated against serum calcium and concurrent supplement needs.

Starting dose, titration, and monitoring are set by the treating physician; no self-dosing guidance is provided here.

Side effects & safety profile

Reported adverse effects in trials include injection-site reactions, headache, and dysregulation of calcium (both hypercalcemia and hypocalcemia), particularly during dose titration, so close monitoring of serum and urinary calcium is required.

As a parathyroid hormone analog it must be titrated by a clinician; this educational page does not replace endocrinology care, and long-term safety continues to be studied.

Stacking & combinations

During treatment, conventional calcium and active vitamin D are typically tapered rather than stacked, and dose changes are physician-directed, not combined with other peptides.

Finding Palopegteriparatide vendors

Finding Palopegteriparatide vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Sign in to review

Frequently asked questions

It is approved for the treatment of chronic hypoparathyroidism in adults, replacing missing parathyroid hormone activity.

References

  1. [1] Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial — Khan AA et al., Journal of Bone and Mineral Research 2023. PMID: 36271471. View sourceStudy: Randomized controlled phase 3 trialAt 26 weeks most patients achieved normal serum calcium while independent of active vitamin D and therapeutic calcium.
  2. [2] Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial — Clarke BL et al., Journal of Clinical Endocrinology and Metabolism 2025. PMID: 39376010. View sourceStudy: Randomized controlled phase 3 trial (52-week)Normal calcium and independence from conventional therapy were sustained through 52 weeks.
  3. [3] Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial — Rejnmark L et al., Advances in Therapy 2024. PMID: 38691316. View sourceStudy: Phase 3 trial analysis (1-year)Renal function improved over one year of palopegteriparatide treatment.
  4. [4] Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial — Rejnmark L et al., Journal of Bone and Mineral Research 2026. PMID: 42166177. View sourceStudy: Phase 3 trial analysis (2-year)Renal function improvement was sustained through two years of treatment.
  5. [5] Palopegteriparatide in Japanese adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway Japan trial — Ashida K et al., Endocrine Journal 2026. PMID: 41260697. View sourceStudy: Phase 3 multicenter trialEfficacy and safety in Japanese adults were consistent with the global PaTHway results over 52 weeks.
This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.